Drugs / BZT2312
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06249256 | Jun 2023 → Jun 2026 overdue | cancer | Shanghai Cell Therapy Group Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BZT2312 | “The main aim of this study is to determin the safety and efficacy of BZT2312 in patients with solid tumors.” NCT06249256 ↗ |
| Modality | Cell therapy | “autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells” NCT06249256 ↗ |
| Route | Intravenous | “by intravenous (IV) injection” NCT06249256 ↗ |
| Target | MSLN | “mesothelin (MSLN)-targeted” NCT06249256 ↗ |